Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Abel Cordoba is active.

Publication


Featured researches published by Abel Cordoba.


PLOS ONE | 2014

Feasibility Study of Pelvic Helical IMRT for Elderly Patients with Endometrial Cancer

Jean-Emmanuel Bibault; Philippe Nickers; Emmanuelle Tresch; Abel Cordoba; Eric Leblanc; Pauline Comte; T. Lacornerie; E. Lartigau

Purpose Standard treatment for early-stage endometrial cancer involves surgery (when possible) followed by brachytherapy or external-beam radiotherapy (EBRT) for high-risk tumors. EBRT is not without toxicity, meaning that it could be difficult to complete for elderly patients, who typically have decreased reserve and resistance to stressors. Patients and methods Patients aged 70 and over treated between April 2009 and May 2013 for endometrial cancer and received IMRT (Intensity-Modulated Radiation Therapy) were included in this observational study. IMRT could be performed as adjuvant treatment or as an exclusive treatment for patients not amenable to surgery. The primary endpoints of this study were to assess the feasibility and toxicity of pelvic IMRT in this population. Secondary endpoints were to assess disease-specific survival, overall survival, and local control. Predictors of toxicity were also explored. Results Forty seven consecutive patients were included in the analysis. Median age at diagnosis was 75 years (range, 70–89 years). Eleven patients were aged 80 years and older. Toxicities were found in thirty four patients (72%) during treatment. Among these, toxicity did not exceed grade 2 for 32 patients (68%). Two patients had a grade 3 toxicity (4%). Overall survival rates were 87% and 83% at 1 and 2 years, respectively. Six patients (12.8%) had a local relapse and nine others (19.1%) had distant relapse. Conclusions Pelvic helical IMRT for patients aged 70 and older is feasible with full standard radiation doses, showing that age greater than 70 should not be considered as a reason not to perform optimal treatment.


Gynecologic Oncology | 2017

Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy

Henri Azaïs; Louise Ghesquière; Clothilde Petitnicolas; Yves Borghesi; Emmanuelle Tresch-Bruneel; Abel Cordoba; Fabrice Narducci; Lucie Bresson; Eric Leblanc

BACKGROUND Extended-field chemoradiation therapy is usually performed in patients with locally advanced cervical cancer (LACC) and paraaortic (PA) node metastases. Considering the very low rate of skip metastases above inferior mesenteric artery, ilio-inframesenteric paraaortic lymph node dissection (IM-PALND) seems to be an adequate pattern of PALND. Our objective was to assess the accuracy of this management to determine PA nodal status in comparison with infrarenal paraaortic lymphadenectomy (IR-PALND) in case of squamous or glandular cervical cancer. METHODS All patients with LACC and negative MRI and PET/CT imaging at paraaortic level had laparoscopic staging (followed, if negative, by extraperitoneal paraaortic lymphadenectomy). From January 2011 to September 2015, patients who had IM-PALND were included and were compared to a previous historical series of IR-PALND patients. The two groups differed only at the upper level of dissection. Characteristics of nodal involvement at paraaortic level depending on level of dissection, PET/CT imaging and histology were studied. RESULTS 119 women were included in our study, with 56 patients in the IM-PALND group and 63 in the IR-PALND group. In the IM-PALND group, fewer nodes were resected (p<0.001). There was no difference between the two groups regarding nodal status at paraaortic level (p=0.77). Patterns of nodal involvement were similar whichever the histological subtype of cervical cancer (squamous or glandular). CONCLUSION IM-PALND appears to be equally effective to assess paraaortic nodal involvement in LACC for both histological subtypes - glandular and squamous carcinomas - and to select patients for extended-field chemoradiation therapy.


Journal of Contemporary Brachytherapy | 2017

Locally advanced adenocarcinoma of the cervixon uterus didelphys: a case report

Abel Cordoba; Alexandre Escande; Pauline Comte; Ingrid Fumagalli; Lucie Bresson; Ndaye Mubiayi; Eric Lartigau

In November 2013, a woman with Herlyn-Werner-Wunderlich (HWW) syndrome was diagnosed with a locally advanced left cervical adenocarcinoma. The patient’s malformation consisted of two uteri with two cervixes, a obstructed vagina, and a left renal agenesis. Classification FIGO: stage IIIa because of infiltration of the inferior third of the vagina wall. Locoregional management comprised an infrarenal lateral aortic lymphadenectomy followed by concomitant radio-chemotherapy to the pelvic (inguinal, pelvic, and infrarenal para aortic nodes) volumes. A total of 50.4 Gy were delivered (1.8 Gy/fraction/day) to the node (inguinal, pelvic, and aortic infrarenal) and pelvic volume; a concomitant boost to the primary cervical tumor and macroscopic nodes to 59.92 Gy (2.14 Gy/fraction/day) was performed. 20 Gy were delivered with intracavitary brachytherapy boost with mold technique and a pulsed-dose-rate technique due to the rarity of this uterine malformation. After 30 months of follow-up, there was no evidence of locoregional or distant recurrence.


Annals of Surgical Oncology | 2015

Occult Invasive Cervical Cancer Found After Inadvertent Simple Hysterectomy: Is the Ideal Management: Systematic Parametrectomy With or Without Radiotherapy or Radiotherapy Only?

Fabrice Narducci; Benjamin Merlot; Lucie Bresson; Ninad Katdare; Florence Le Tinier; Abel Cordoba; Charles Fournier; Eric Leblanc


Radiation Oncology | 2016

Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)

Abel Cordoba; Alexandre Escande; Stephanie Lopez; L. Mortier; Xavier Mirabel; Bernard Coche-Dequeant; E. Lartigau


Annals of Surgical Oncology | 2015

Managing Endometrial Cancer: The Role of Pelvic Lymphadenectomy and Secondary Surgery

Yves Borghesi; Fabrice Narducci; Lucie Bresson; Emmanuelle Tresch; Jean Pierre Meurant; Sophie Cousin; Abel Cordoba; Benjamin Merlot; Eric Leblanc


International Journal of Gynecological Cancer | 2017

Morbidity of Staging Inframesenteric Paraaortic Lymphadenectomy in Locally Advanced Cervical Cancer Compared With Infrarenal Lymphadenectomy

Clothilde Petitnicolas; Henri Azaïs; Louise Ghesquière; Emmanuelle Tresch-Bruneel; Abel Cordoba; Fabrice Narducci; Lucie Bresson; Eric Leblanc


Brachytherapy | 2017

Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers

Abel Cordoba; Alexandre Escande; Thomas Leroy; Xavier Mirabel; Bernard Coche-Dequeant; E. Lartigau


Reports of Practical Oncology & Radiotherapy | 2015

Safety of adjuvant intensity-modulated postoperative radiation therapy in endometrial cancer: Clinical data and dosimetric parameters according to the International Commission on Radiation Units (ICRU) 83 report

Abel Cordoba; Philippe Nickers; Emmanuelle Tresch; Bernard Castelain; Eric Leblanc; Fabrice Narducci; Florence Le Tinier; Anne Lesoin; T. Lacornerie; Eric Lartigau


Cancer Radiotherapie | 2017

Cancers du col de l’utérus localement évolués avec atteinte ganglionnaire lomboaortique sur la tomographie par émission de positons au fluorodésoxyglucose : résultats de la chimioradiothérapie lombopelvienne avec modulation d’intensité

A. Carlier; Abel Cordoba; A. Escande; F. Le Tinier; Xavier Mirabel; H. Gauthier

Collaboration


Dive into the Abel Cordoba's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge